3SBio-TNK Joint Venture
Division of 3SBio Inc.
Latest From 3SBio-TNK Joint Venture
As more multinational drug makers divest/license their maturing or non-core assets to local Chinese firms, a fast pick-up in sales in China via these alliances does not always appear to be ensured, at least early on. Scrip delves into one such recent agreement between Lilly and 3SBio, one of China's most successful biotechs.
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.